ELYM ELIEM THERAPEUTICS INC

Climb Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Climb Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

WELLESLEY, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced that members of its executive team will participate at the Oppenheimer 35th Annual Healthcare Life Sciences Conference being held virtually February 11-12, 2025.

Oppenheimer 35th Annual Healthcare Life Sciences Conference

Format: Presentation and one-on-one investor meetings

Date: February 12, 2025

Time: 9:20 a.m. ET

Webcast: 

About Climb Bio, Inc.

Climb Bio, Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s pipeline includes, budoprutug, an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody currently in IND-enabling studies for IgA nephropathy. For more information, please visit .  

Investors

Chris Brinzey

ICR Healthcare



339-970-2843

Media

Jon Yu

ICR Healthcare



475-395-5375



EN
04/02/2025

Underlying

ELYMELIEM THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ELIEM THERAPEUTICS INC

 PRESS RELEASE
Free
ELYM ELIEM THERAPEUT...

Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results ...

Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates  Dosing completed in Phase 1 study of budoprutug subcutaneous formulation, with data expected in H1 2026 Budoprutug clinical trials ongoing in pMN, ITP, and SLE, with initial data from all three trials expected in H2 2026 Enrollment ongoing in CLYM116 Phase 1 healthy volunteer study, with initial data expected mid-2026 Strong financial position with cash runway expected into 2028 WELLESLEY HILLS, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage ...

21h / 8m 1 EN
Laura Chico ... (+2)
  • Laura Chico
  • Thomas Yip
ELYM ELIEM THERAPEUTICS INC
21h / 23m 21h / 23m 1 EN
Wedbush Research
  • Wedbush Research
XNCR XENCOR INC.
WDC WESTERN DIGITAL CORPORATION
STAA STAAR SURGICAL CO.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
NCMI NATIONAL CINEMEDIA INC.
MU MICRON TECHNOLOGY INC.
MNKD MANNKIND CORP.
MCS MARCUS CORPORATION
INTC INTEL CORPORATION
IMAX IMAX CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
CNK CINEMARK HOLDINGS INC.
AXTI AXT INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
AMC AMC ENTERTAINMENT HOLDINGS INC. CLASS A
NFLX NETFLIX INC.
2303 UNITED MICROELECTRONICS CORP.
CCRN CROSS COUNTRY HEALTHCARE INC.
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
TSEM TOWER SEMICONDUCTOR LTD
SMCI SUPER MICRO COMPUTER
RBLX INC.
STX ROBLOX
ELYM SEAGATE TECHNOLOGY HLDGS PLC
TCRX ELIEM THERAPEUTICS INC
GFS TSCAN THERAPEUTICS INC
PEPG GLOBALFOUNDRIES INC
STUB PEPGEN INC
STUBHUB HOLDINGS INC.
03/05/26 March 5, 2026 1 EN
Laura Chico ... (+2)
  • Laura Chico
  • Thomas Yip
ELYM ELIEM THERAPEUTICS INC
03/05/26 March 5, 2026 1 EN
 PRESS RELEASE
Free
ELYM ELIEM THERAPEUT...

Climb Bio to Present at Upcoming Investor Conferences

Climb Bio to Present at Upcoming Investor Conferences WELLESLEY HILLS, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that members of its executive team will participate in the upcoming conferences detailed below. Guggenheim's Emerging Outlook: Biotech SummitFormat: Fireside ChatDate: Thursday, February 12, 2026Time: 3:00 – 3:25 p.m. ET Oppenheimer 36th Annual Healthcare Life Sciences Conference Format: Fireside ChatDate: Wednesday, Februar...

February 5, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch